CA2686722C - Methods for treating and preventing gi syndrome and graft versus host disease - Google Patents

Methods for treating and preventing gi syndrome and graft versus host disease Download PDF

Info

Publication number
CA2686722C
CA2686722C CA2686722A CA2686722A CA2686722C CA 2686722 C CA2686722 C CA 2686722C CA 2686722 A CA2686722 A CA 2686722A CA 2686722 A CA2686722 A CA 2686722A CA 2686722 C CA2686722 C CA 2686722C
Authority
CA
Canada
Prior art keywords
asmase
ceramide
antibody
cells
radiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2686722A
Other languages
English (en)
French (fr)
Other versions
CA2686722A1 (en
Inventor
Jimmy Rotolo
Richard Kolesnick
Renate Pasqualini
Wadih Arap
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Memorial Sloan Kettering Cancer Center
Original Assignee
The University of Texas System
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System, Memorial Sloan Kettering Cancer Center filed Critical The University of Texas System
Publication of CA2686722A1 publication Critical patent/CA2686722A1/en
Application granted granted Critical
Publication of CA2686722C publication Critical patent/CA2686722C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
CA2686722A 2007-05-06 2008-05-06 Methods for treating and preventing gi syndrome and graft versus host disease Active CA2686722C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91629807P 2007-05-06 2007-05-06
US60/916,298 2007-05-06
PCT/US2008/062789 WO2008137901A2 (en) 2007-05-06 2008-05-06 Methods for treating and preventing gi syndrome and graft versus host disease

Publications (2)

Publication Number Publication Date
CA2686722A1 CA2686722A1 (en) 2008-11-13
CA2686722C true CA2686722C (en) 2017-08-15

Family

ID=39944232

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2686722A Active CA2686722C (en) 2007-05-06 2008-05-06 Methods for treating and preventing gi syndrome and graft versus host disease

Country Status (6)

Country Link
US (6) US8562993B2 (enExample)
EP (1) EP2152287B1 (enExample)
JP (2) JP5924863B2 (enExample)
AU (1) AU2008247368B2 (enExample)
CA (1) CA2686722C (enExample)
WO (1) WO2008137901A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2152287B1 (en) 2007-05-06 2014-04-02 Sloan Kettering Institute For Cancer Research Methods for treating and preventing gi syndrome and graft versus host disease
US20100255514A1 (en) * 2007-08-16 2010-10-07 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
CA2733672C (en) 2007-08-16 2018-09-11 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
US20130203081A1 (en) * 2010-04-13 2013-08-08 Janusz Rak Tumor cell-derived microvesicles
US10722577B2 (en) * 2012-05-25 2020-07-28 Sloan Kettering Institute For Cancer Research Methods for treating GI syndrome and graft versus host disease
SG11201700787XA (en) 2014-08-07 2017-02-27 Sloan Kettering Inst Cancer Anti-ceramide antibodies
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11512289B2 (en) * 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
JP6803339B2 (ja) 2015-04-21 2020-12-23 エンリヴェックス セラピューティクス リミテッド 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用
WO2017119988A2 (en) * 2015-12-10 2017-07-13 Memorial Sloan Kettering Cancer Center Radioprotection by wnt activation
JP6884155B2 (ja) 2016-02-18 2021-06-09 エンリヴェックス セラピューティクス リミテッド 癌治療のための併用免疫療法及びサイトカイン制御療法
WO2018195070A1 (en) * 2017-04-17 2018-10-25 Memorial Sloan-Kettering Cancer Center Gut-protective effect of rig-i/mavs and sting activation
US20200362057A1 (en) * 2019-05-16 2020-11-19 Snake River Bioscience, Inc. Compositions and methods for the treatment of major depressive disorder
US10975169B1 (en) 2019-09-27 2021-04-13 Memorial Sloan Kettering Cancer Center Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2
CN112255221A (zh) * 2020-10-16 2021-01-22 航科中投生物技术（北京）有限公司 一种生物防护过滤介质浓度及喷涂效果的比色鉴定方法
BR112023018758A2 (pt) * 2021-03-16 2023-11-28 Univ Michigan State Intensificação de cicatrização de ferida com anticorpos anticeramida
US20240180920A1 (en) * 2021-03-23 2024-06-06 Spinogenix, Inc. Certain fascin binding compounds for spinogenesis
IL327627A (en) * 2023-10-04 2026-06-01 Memorial Hospital For Cancer And Allied Diseases Combination administration of bone marrow and anti-ceramide antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950649A (en) 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
JPH02128697A (ja) * 1988-11-09 1990-05-17 Hoechst Japan Ltd 抗フコシルセラミドモノクローナル抗体
US5643602A (en) 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
US5851548A (en) 1995-06-07 1998-12-22 Gen-Probe Incorporated Liposomes containing cationic lipids and vitamin D
US5711964A (en) 1995-06-07 1998-01-27 United States Of America Method for the intracellular delivery of biomolecules using liposomes containing cationic lipids and vitamin D
AU2588297A (en) 1996-04-04 1997-10-29 Ortho Pharmaceutical Corporation Liposome-based topical vitamin d formulation
EP0937258A2 (en) 1996-10-29 1999-08-25 Fred Hutchinson Cancer Research Center, Inc. Cell stress regulated human mhc class i gene
AU2002211681A1 (en) * 2000-10-12 2002-04-22 Curagen Corporation Proteins and nucleic acids encoding same
US20040023390A1 (en) 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
DE10239531A1 (de) * 2002-08-23 2004-03-04 Gulbins, Erich, Prof. Dr. Prophylaxe und Therapie von Infektionserkrankungen
CA2531878A1 (en) 2003-05-09 2005-03-24 Curagen Corporation Therapeutic use of g53135-05(fgf-20) in radiation protection
KR100565437B1 (ko) 2003-07-31 2006-03-30 중앙대학교 산학협력단 신규한 스핑고마이엘리나제 효소, 그에 대한 항체, 안티센스 및 제조방법
EP1904101A4 (en) 2005-06-08 2011-06-15 Univ Duke ANTI-CD19 ANTIBODY THERAPY FOR TRANSPLANTATION
WO2007095594A2 (en) 2006-02-14 2007-08-23 Cellerant Therapeutics, Inc. Methods and compositions for enhancing engraftment of hematopoietic stem cells
EP2152287B1 (en) 2007-05-06 2014-04-02 Sloan Kettering Institute For Cancer Research Methods for treating and preventing gi syndrome and graft versus host disease

Also Published As

Publication number Publication date
JP2010526153A (ja) 2010-07-29
US20220354861A1 (en) 2022-11-10
EP2152287A2 (en) 2010-02-17
US20190046538A1 (en) 2019-02-14
JP5924863B2 (ja) 2016-05-25
US12121525B2 (en) 2024-10-22
AU2008247368A1 (en) 2008-11-13
US11207329B2 (en) 2021-12-28
JP6251234B2 (ja) 2017-12-20
US9592238B2 (en) 2017-03-14
US8562993B2 (en) 2013-10-22
JP2016121154A (ja) 2016-07-07
CA2686722A1 (en) 2008-11-13
US20100239572A1 (en) 2010-09-23
US20250325559A1 (en) 2025-10-23
EP2152287A4 (en) 2011-06-29
US20140112932A1 (en) 2014-04-24
US20170273987A1 (en) 2017-09-28
WO2008137901A2 (en) 2008-11-13
AU2008247368B2 (en) 2013-10-10
WO2008137901A9 (en) 2009-04-30
WO2008137901A8 (en) 2009-06-11
EP2152287B1 (en) 2014-04-02
WO2008137901A3 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
US12121525B2 (en) Methods for treating GI syndrome and graft versus host disease
AU2020201804B2 (en) Methods for inhibiting fibrosis in a subject in need thereof
US10273306B2 (en) Antibodies directed against ICOS for treating graft-versus-host disease
CN101720232B (zh) 具有修饰的效应器功能的fc受体结合型多肽
AU2008285626B2 (en) Use of TLR-2 antagonists for treatment of reperfusion injury and tissue damage
AU2021221880A1 (en) Combination immune therapy and cytokine control therapy for cancer treatment
CN114127121A (zh) 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物
KR20140021708A (ko) 항-pcsk9 항체를 사용한 치료
CN113795506A (zh) 用于治疗CD1a阳性癌症的CAR T细胞
US20250388687A1 (en) Epo receptor agonists and antagonists
US20250099542A1 (en) Method of treating a tumor with a combination of il-7 protein and vegf antagonist
WO2014085808A1 (en) Methods for improving thymic recovery and preventing and treating graft versus host disease using ccr2 and ccr5 antagonists
JP2022514867A (ja) 移植片対宿主病（ＧｖＨＤ）の防止又は処置のための抗ＣＣＲ７ ＭＡＢの使用
US20250326831A1 (en) Methods for treating disease using psmp antagonists
KR20250006965A (ko) 호산구에 의해 유발되는 질환 및 장애의 치료를 위한 방법 및 조성물
HK40049374A (en) Use of anti-ccr5 antibodies in graft versus host disease
Ferrer Immunomodulation in Transplantation: Promoting Tolerance and Protective Immunity

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250311

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250311

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250311

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260317

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260317